0KF3 Stock Overview
A biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Palatin Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.13 |
| 52 Week High | US$5.45 |
| 52 Week Low | US$0.70 |
| Beta | 0.94 |
| 11 Month Change | 0.71% |
| 3 Month Change | -31.41% |
| 1 Year Change | -40.03% |
| 33 Year Change | -93.00% |
| 5 Year Change | n/a |
| Change since IPO | -95.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0KF3 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 12.8% | 1.5% | 2.2% |
| 1Y | -40.0% | -17.9% | 8.8% |
Return vs Industry: 0KF3 underperformed the UK Biotechs industry which returned -17.9% over the past year.
Return vs Market: 0KF3 underperformed the UK Market which returned 8.8% over the past year.
Price Volatility
| 0KF3 volatility | |
|---|---|
| 0KF3 Average Weekly Movement | 20.1% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0KF3's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0KF3's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 30 | Carl Spana | palatin.com |
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases.
Palatin Technologies, Inc. Fundamentals Summary
| 0KF3 fundamental statistics | |
|---|---|
| Market cap | US$21.50m |
| Earnings (TTM) | -US$32.35m |
| Revenue (TTM) | US$2.38m |
9.0x
P/S Ratio-0.7x
P/E RatioIs 0KF3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0KF3 income statement (TTM) | |
|---|---|
| Revenue | US$2.38m |
| Cost of Revenue | US$23.23m |
| Gross Profit | -US$20.84m |
| Other Expenses | US$11.51m |
| Earnings | -US$32.35m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.66 |
| Gross Margin | -874.25% |
| Net Profit Margin | -1,357.06% |
| Debt/Equity Ratio | 0% |
How did 0KF3 perform over the long term?
See historical performance and comparison